interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Erdafitinib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Erdafitinib, and who makes it?

Erdafitinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Erdafitinib1 dosage-form group in the Orange Book
0generic makers listed
  1. Erdafitinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Balversa. No generic is listed as marketed.

20152020202520302035204001brand 2019data datePatent 9464071 listed to expire 28 April 2031Patent 8895601 listed to expire 12 April 2033Patent 9902714 listed to expire 26 March 2035Patent 12037644 listed to expire 18 October 2035Patent 10898482 listed to expire 9 February 2036Patent 11684620 listed to expire 9 February 2036Patent 12678498 listed to expire 13 June 2036Patent 10478494 listed to expire 13 August 2036Patent 11077106 listed to expire 2 February 2038Exclusivity I-930 to 19 January 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 19 January 2027Exclusivity I-930 Balversa
  • 28 April 2031Patent 9464071
  • 12 April 2033Patent 8895601 drug substance
  • 26 March 2035Patent 9902714 drug product
  • 18 October 2035Patent 12037644
  • 9 February 2036Patent 10898482 drug product
  • 9 February 2036Patent 11684620
  • 13 June 2036Patent 12678498
  • 13 August 2036Patent 10478494

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.